CUMBERLAND PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,862,402 | $11,444,693 |
| Accounts receivable, net | 13,419,594 | 16,944,780 |
| Inventories, net | 29,935 | 29,935 |
| Prepaid and other current assets | 675,993 | 654,166 |
| Current assets held for sale/related to discontinued operations | 15,653,221 | 7,986,693 |
| Total current assets | 33,641,145 | 37,060,267 |
| Non-current inventories | 40,879 | 40,879 |
| Property and equipment, net | 248,808 | 264,724 |
| Intangible assets, net | 43,804 | 53,621 |
| Operating lease right-of-use assets | 7,281,280 | 5,781,728 |
| Other assets | 3,171,623 | 2,973,378 |
| Assets held for sale/related to discontinued operations | 18,452,155 | 30,649,395 |
| Total assets | $62,879,694 | $76,823,992 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $19,554,251 | $18,567,546 |
| Operating lease current liabilities | 503,016 | 467,774 |
| Pre-close accrued liabilities | 7,518,645 | 7,774,143 |
| Other current liabilities | 2,242,122 | 2,855,952 |
| Current liabilities held for sale/related to discontinued operations | 5,375,104 | 7,079,504 |
| Total current liabilities | 35,193,138 | 36,744,919 |
| Revolving line of credit - long term | — | 5,240,733 |
| Operating lease non-current liabilities | 4,211,168 | 4,471,965 |
| Other long-term liabilities | 3,981,224 | 3,626,875 |
| Liabilities held for sale/related to discontinued operations | 2,387,716 | 2,195,278 |
| Total liabilities | 45,773,246 | 52,279,770 |
| Equity: | ||
| Shareholders’ equity: | ||
| Common stock— no par value; 100,000,000 shares authorized; 14,983,107 and 14,956,627 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively | 51,808,088 | 51,684,381 |
| Accumulated deficit | (34,370,075) | (26,804,059) |
| Total shareholders’ equity | 17,438,013 | 24,880,322 |
| Noncontrolling interests | (331,565) | (336,100) |
| Total equity | 17,106,448 | 24,544,222 |
| Total liabilities and equity | $62,879,694 | $76,823,992 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.